In particular, the immunoassay department at NUVISAN has a frequent need to minimize the use of biological sample material. Dr Uwe Kärcher, Director Immunoassays, explains, “Gyrolab technology enables us to perform nanoliter-scale assays with very small sample volumes. This can be important in the case of early phase discovery projects, the analysis of rare matrix, or special circumstances such as pediatric studies where only small volumes of sample may be available. Through the conservation of resources and material, bioanalysis is thus more sustainable. We think sustainability regarding animal and patient matrices is very important and Gyros Protein Technologies offers uniquely a forward-looking perspective in this regard.”
The immunoassay department at NUVISAN has also appreciated another key advantage of the Gyrolab platform — that being the easy transfer of assay from clients and minimal hands-on time needed to perform an analytical run. Added to that, they have seen that the automated system minimizes intra-/inter-run variations and provides the high throughput needed to manage large numbers of samples. Nuvisan also values the high quality and easy-going handling and setup of the Gyrolab generic kits, which are successfully used for discovery studies and need just a few transfer experiments to be specifically adapted to their sponsor’s requirements. Dr Uwe Kärcher adds, “While being very robust, at the same time Gyrolab technology is still open and flexible for assay optimization. The Gyrolab system enables us to conserve resources including time and matrix without losing performance. This makes the system unique and a very valuable tool that allows us to work more efficiently.”
“The clever technology of the Gyrolab system using centrifugal and capillary forces to transport the sample and thus to have minimal interaction times is unique and gives advantages that other platforms cannot provide”, says Katja Zeiser, project manager and subject matter expert for biomarkers at the immunoassay department. “Especially when we’re talking about assays to measure total/bound analyte, the Gyrolab can make a huge difference if complexes are not stable or have low affinity. Furthermore, with the Gyrolab software showing the binding profiles of the sample we can check for data trends and simplify troubleshooting. These possibilities given by the Gyrolab platform allows us as Science CRO to provide even better support and scientific advice to the clients.”
Dr Uwe Kärcher also states that NUVISAN is very pleased with the commitment from Gyros Protein Technologies. “The company provides extraordinary support and focuses on good communication, a trait also embodied at NUVISAN. It is a very congenial supplier relationship with Gyros Protein Technologies providing quick and capable answers to our questions. We were able to gain a lot of experience with Gyrolab assay development by having such a great interaction with the Gyros Protein Technologies service team. Their support is excellent, outstanding within the bioanalysis environment, and we are happy to work with them.”
About NUVISAN
NUVISAN’s immunoassay department offers different types of ligand binding assays for analysis of protein/peptide molecules as well as cell-based assays/flow cytometry using state-of-the-art equipment. Our services include method development, transfer, and validation as well as bioanalysis of biological samples from in-house (pre-clinical and clinical) and external studies. Our expertise covers, inter alia, assays to support pharmacokinetic, immunogenicity, biomarker, and biosimilar studies.
The NUVISAN group is a contract research and development and manufacturing organization (CRO/CDMO) with five sites in Germany and France as well as local experts situated in Latin America. We offer unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain to our biotech startup, pharma, non-profit, and venture capital clients – from target identification to the patient.
Thanks to more than 40 years of experience and about 1,000 employees (incl. > 70 % industry-experienced scientists and lab professionals), we know how to discover, develop, and bring the next generation of medicines to market. At the same time, our scientists understand that every project is different. With a flexible and innovative approach and transparent communication, our teams are passionate about closely collaborating with our sponsors to adapt to their individual needs.
